Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

ClinicalTrials.gov ID: NCT00245388

Public ClinicalTrials.gov record NCT00245388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, dose-ranging, placebo-controlled trial to determine the lipid-lowering efficacy and safety of BMS-298585 (muraglitazar) alone in combination with pravastatin in subjects with mixed dyslipidemia.

Study identification

NCT ID
NCT00245388
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
330 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2002
Primary completion
Not listed
Completion
Jun 30, 2002
Last update posted
Apr 22, 2012

2002

United States locations

U.S. sites
53
U.S. states
24
U.S. cities
53
Facility City State ZIP Site status
Local Institution Phoenix Arizona
Local Institution Little Rock Arkansas
Local Institution Irvine California
Local Institution Long Beach California
Local Institution Raleigh California
Local Institution Roseville California
Local Institution Sacramento California
Local Institution San Diego California
Local Institution Santa Ana California
Local Institution Longmont Colorado
Local Institution Clearwater Florida
Local Institution Cooper City Florida
Local Institution DeLand Florida
Local Institution Inverness Florida
Local Institution Longwood Florida
Local Institution Pembroke Pines Florida
Local Institution Sarasota Florida
Local Institution Stuart Florida
Local Institution Dunwoody Georgia
Local Institution Melbourne Georgia
Local Institution Peoria Illinois
Local Institution Indianapolis Indiana
Local Institution Iowa City Iowa
Local Institution Overland Park Kansas
Local Institution Wichita Kansas
Local Institution Louisville Kentucky
Local Institution Marrero Louisiana
Local Institution Baltimore Maryland
Local Institution Bethesda Maryland
Local Institution Edina Minnesota
Local Institution Minneapolis Minnesota
Local Institution Kansas City Missouri
Local Institution St Louis Missouri
Local Institution Toms River New Jersey
Local Institution Manlius New York
Local Institution Hickory North Carolina
Local Institution Winston-Salem North Carolina
Local Institution Columbus Ohio
Local Institution Bend Oregon
Local Institution Hillsboro Oregon
Local Institution Portland Oregon
Local Institution Philadelphia Pennsylvania
Local Institution Sellersville Pennsylvania
Local Institution Warminster Pennsylvania
Local Institution Greer South Carolina
Local Institution Mt. Pleasant South Carolina
Local Institution Austin Texas
Local Institution Dallas Texas
Local Institution San Angelo Texas
Local Institution San Antonio Texas
Local Institution Olympia Washington
Local Institution Seattle Washington
Local Institution Yakima Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00245388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2012 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00245388 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →